Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $193.1 billion.

  • Addex Therapeutics' Other Working Capital Changes fell 5982.36% to $193.1 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $12.9 billion, marking a year-over-year decrease of 9841.38%. This contributed to the annual value of -$186741.9 for FY2024, which is 41415.67% down from last year.
  • As of Q2 2025, Addex Therapeutics' Other Working Capital Changes stood at $193.1 billion, which was down 5982.36% from -$177.8 billion recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Other Working Capital Changes ranged from a high of $480.5 billion in Q2 2024 and a low of -$815.3 billion during Q2 2023
  • Moreover, its 4-year median value for Other Working Capital Changes was $341877.7 (2022), whereas its average is $608.8 million.
  • Within the past 5 years, the most significant YoY rise in Addex Therapeutics' Other Working Capital Changes was 6835027257.35% (2023), while the steepest drop was 70478289808.47% (2023).
  • Over the past 4 years, Addex Therapeutics' Other Working Capital Changes (Quarter) stood at $568069.9 in 2022, then soared by 68350272.57% to $388.3 billion in 2023, then crashed by 43.86% to $218.0 billion in 2024, then dropped by 11.44% to $193.1 billion in 2025.
  • Its Other Working Capital Changes was $193.1 billion in Q2 2025, compared to -$177.8 billion in Q1 2025 and $218.0 billion in Q4 2024.